Hemophilia B Gene Therapy Continues to Reduce Bleeding

by | Jan 26, 2026 | Health

Spread the love
Researchers complete final analysis of a phase 3 study of men with hemophilia B receiving intravenous etranacogene dezaparvovec.
Medscape Medical News

Written By

Written by Albert Pham, News Curator and Blogger

Related Posts

0 Comments